Zai Lab initiated with bullish view at Morgan Stanley, here’s why

Morgan Stanley analyst Jack Lin initiated coverage of Zai Lab with an Overweight rating and $47.50 price target. Zai Lab, a “biotech leader” in China’s in-licensing strategy space, should benefit as in-licensing names re-rate under favorable tailwinds with 40% of its pipeline having “first-in-class potential,” the analyst tells investors.